Verona Stock Soars After $200m Placement For COPD Drug
Fundraise Nearly Quadruples Market Cap
Executive Summary
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.
You may also be interested in...
Verona Emerges Victorious From Second COPD Trial
After once again showing significant improvements in lung function and a 36% reduction in rate of exacerbations over 24 weeks, Verona is confident that its dual PDE3/4 inhibitor will change the treatment paradigm for COPD.
Verona Boosts Funds And Becomes Potential Takeover Target
The UK biotech is in a strong spot after extending its cash runway to prepare for the launch of ensifentrine, which analysts believe could become a pipeline-in-a-molecule for respiratory diseases.
UK Biotechs Look Destined To Remain Bit Players
Another promising British-based company, GW Pharma, has been acquired, this time by mid-sized US player Jazz. Is it a pipedream that a UK biotech could be in a position to pull off a $7bn takeover of its own or does it really not matter?